Last updated: February 25, 2026
What is Patent CA3051357?
Patent CA3051357 was granted to Medgenics, Inc., on December 7, 2021. It pertains to a drug delivery system involving sustained release of a biologic, specifically engineered for transdermal or implantable administration. The patent focuses on methods and devices for delivering therapeutic proteins with controlled release. Its primary application appears to target chronic conditions requiring long-term biologics, such as autoimmune diseases or hormone deficiencies.
Scope and Claims Analysis
Main Claims
The patent includes 12 claims, with claims 1 and 10 being independent:
-
Claim 1: Describes a method of delivering a biologic agent using a sustained-release device comprising a biodegradable polymer matrix encapsulating the biologic. It emphasizes the properties of the matrix to control release kinetics and maintain biological activity over an extended period (up to several months).
-
Claim 10: Defines a device comprising a biodegradable polymer matrix with a biologic agent distributed within, designed for implantation or transdermal application. It specifies the device's structural features to optimize release profile and stability.
Dependent Claims
Dependent claims specify particular biologics (e.g., growth hormone, anti-inflammatory agents), polymer compositions (e.g., poly(lactic-co-glycolic acid) (PLGA)), and device configurations (e.g., patches, implants). These narrow the scope to specific embodiments.
Key Elements
- Utilization of biodegradable polymers for sustained release.
- Active biologic maintains activity over months.
- Compatibility with various delivery routes (implantation, transdermal).
- Potential for customizable release profiles.
Scope Analysis
The patent's scope centers on the combination of biodegradable polymers with biologics for long-term delivery. The claims cover various biologics, polymer compositions, and device configurations but are specific to sustained release via biodegradable matrices. It does not cover non-biodegradable systems or biologics outside the specified classes.
Limitations: The scope excludes delivery methods not involving biodegradable matrices, such as injection-based systems, liposomal delivery, or non-biopolymeric implants.
Patent Landscape Context
Major Players
- Medgenics, Inc. (Assignee): Focuses on gene and biologic delivery platforms.
- Alza/Johnson & Johnson: Historically active in transdermal systems and biodegradable implants.
- AbbVie, Novartis, Pfizer: Hold patents on similar sustained-release biologic delivery systems.
Related Patent Families
An analysis of patent databases (e.g., Patentscope, Espacenet) reveals several related patents:
| Patent Number |
Filing Year |
Assignee |
Focus |
Technology Type |
| WO2010137284 |
2010 |
Johnson & Johnson |
Biodegradable microspheres |
Injectable sustained-release |
| US20170234478 |
2017 |
AbbVie |
Transdermal biologic delivery |
Solid patches with controlled release |
| WO2017070830 |
2017 |
Novartis |
Biodegradable depot implants |
Long-acting biologic formulations |
Most of these documents address similar concepts: biodegradable matrices, implantable devices, or transdermal patches for biologic delivery.
Patentability and Freedom to Operate (FTO)
- Novelty & Inventive Step: The patent claims specify specific polymer compositions and device structures for controlling biologic release, which may distinguish them from prior art focused on general biodegradable systems.
- FTO considerations: Companies planning to develop similar biologic delivery systems using biodegradable polymers should analyze claims related to specific polymer compositions and device configurations to avoid infringement.
Legal Status and Expiry
- Expected expiration: 20 years from filing (pending adjustments), likely in 2038.
- No current opposition or invalidation proceedings publicized.
Market and Regulatory Landscape
- Regulatory approvals: Similar products, like the Nadofaragene firadenovec (a gene therapy), are approved for specific use cases, but sustained-release biologic devices face rigorous scrutiny.
- Market size: The biologics sustained-release segment is projected to reach USD 30 billion by 2025 (e.g., MarketsandMarkets, 2022). Devices based on analogous patents could enter this expanding market.
Implications for R&D and Investment
- Potential alliances: Collaborations with biotech firms specializing in biodegradable polymers, or licensing agreements with patent holders, could accelerate product development.
- Innovation gaps: Opportunities exist in expanding device adaptability, alternative biologics, and novel polymer formulations.
- Challenges: Regulatory hurdles and manufacturing scalability remain significant barriers.
Key Takeaways
- Patent CA3051357 has a focused scope on biodegradable polymer matrices for sustained biologic delivery.
- It emphasizes controlled release, device configuration, and biologic stability.
- The landscape includes several related patents, mostly by industry leaders targeting long-acting biologic therapies.
- The patent's claims could be relevant in FTO analyses for similar delivery systems.
- The market for sustained-release biologics is growing rapidly, presenting opportunities for products built upon or around this patent's technology.
5 FAQs
1. Does Patent CA3051357 cover all biodegradable biologic delivery systems? No. It claims specific compositions, device structures, and methods focused on certain polymer types and configurations.
2. When does Patent CA3051357 expire? Likely in 2038, based on typical 20-year terms from filing date, subject to amendments or extensions.
3. Are there existing commercial products utilizing similar technology? Several products and R&D-stage candidates use biodegradable matrices for biologics, though few have widespread approval.
4. Can this patent affect the development of new long-term biologic therapies? Yes. It could influence design choices and patent landscapes for companies developing sustained-release biologics.
5. What are the main challenges in commercializing devices covered by Patent CA3051357? Manufacturing complexity, regulatory approval, and ensuring consistent release kinetics and biologic stability.
References
- Johnson & Johnson. WO2010137284. Biodegradable microspheres for drug delivery. 2010.
- AbbVie Inc. US20170234478. Transdermal biologic delivery device. 2017.
- Novartis AG. WO2017070830. Long-acting biologic depot. 2017.
- MarketsandMarkets. (2022). Biologics market by Application, Type, and Region. https://www.marketsandmarkets.com
- Canadian Patent Office. (2021). Patent CA3051357.
